Structuring of a Lung Cancer Screening Program Including Clinical, Radiological and Biological Phenotyping Useful for the Development of Individualized Risk Prediction Tools: PREVALUNG ETOILE

NAActive, not recruitingINTERVENTIONAL

Enrollment

160

Participants

Timeline

Start Date

January 23, 2023

Primary Completion Date

June 1, 2024

Study Completion Date

June 1, 2024

Conditions

Smoking-related PathologyAtheromaChronic BronchitisNon-progressive Cancer > 5 YearsLung Cancer

Interventions

DEVICE

thoracic scan Low dose

within 3 months after the V0 visit

BIOLOGICAL

BLOOD SAMPLE

within 3 months after the V0 visit

BIOLOGICAL

FECES SAMPLE

within 3 months after the V0 visit

Trial Locations (1)

Assistance Publique Hopitaux de Marseille, Marseille

All Listed Sponsors

lead

Assistance Publique Hopitaux De Marseille

OTHER